Divi’s Laboratories Ltd

is a global leader in custom synthesis and active pharmaceutical ingredients (APIs) for generics and big pharma. The company posted consistent quarterly revenue between ₹2,142–2,623 crore during FY25, maintaining strong profit margins of 20–26%. Net profit for Q1 FY25 was ₹557 crore with operating profit margin at 36.57% and EPS at ₹20.95. Divi’s benefits from exports, R&D capabilities, and low debt but faces risk from sector regulations and raw material volatility